| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENTA | Common Stock | Sale | -$64.8K | -4.3K | -15.2% | $15.07 | 24K | Jul 11, 2024 | Direct | F1, F2 |
| transaction | ENTA | Common Stock | Sale | -$34.2K | -2.27K | -9.47% | $15.04 | 21.7K | Jul 12, 2024 | Direct | F1, F3 |
| transaction | ENTA | Common Stock | Options Exercise | $48.3K | +5.38K | +24.75% | $8.99 | 27.1K | Jul 15, 2024 | Direct | |
| transaction | ENTA | Common Stock | Sale | -$91.8K | -5.38K | -19.84% | $17.08 | 21.7K | Jul 15, 2024 | Direct | F1, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENTA | Stock Option (Right to Buy) | Options Exercise | $0 | -5.38K | -6.25% | $0.00 | 80.6K | Jul 15, 2024 | Common Stock | 5.38K | $8.99 | Direct | F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. |
| F4 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive. |
| F5 | The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023). |
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2-4 above.